BIOGEN - Key Persons


Alexander J. Denner

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Chairman of Our Corporate Governance Committee
  • Director and Chair, Corporate Governance Committee
Alexander J. Denner, Ph.D., joined our Board of Directors in 2009. Dr. Denner serves as Chair of our Corporate Governance Committee. Dr. Denner is a founding partner and Chief Investment Officer of Sarissa Capital Management LP., a registered investment advisor. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. From 2006 to 2011 Dr. Denner served as a Senior Managing Director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm.

Alfred W. Sandrock - EVP

Job Titles:
  • Executive Vice President
  • Executive Vice President / Research & Development
Alfred W. Sandrock, Jr., M.D., Ph.D., is Executive Vice President, Research & Development at Biogen and has served on the Executive Committee since 2015. He has served as the head of Research & Development since October 2019 and was our Chief Medical Officer from 2012 until January 2020. Since joining the company in 1998, he has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.

Alphonse Galdes - EVP

Job Titles:
  • Executive Vice President
  • Member of the Executive Leadership Team
Alphonse Galdes, Ph.D., is Executive Vice President, Pharmaceutical Operations and Technology of Biogen and has served on the Executive Committee since September 2019. Since joining Biogen in 1995, Dr. Galdes has held several senior executive positions, including most recently as Senior Vice President, Asset Development and Portfolio Management from November 2015 to September 2019 and Senior Vice President, Technical Development from October 2010 to November 2015. Dr. Galdes received his B.Sc. in Chemistry and Biology and his M.Sc. in Biochemistry from the University of Malta and received his Ph.D. in Biochemistry from Oxford University, where he was a Rhodes Scholar. Dr. Galdes performed post-doctoral research work at the Department of Biological Chemistry at Harvard Medical School.

Brian S. Posner

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Compensation and Management Development Committee
  • Member of Our Compensation Management
  • Member of the Board of Directors of Arch Capital Group Ltd
Brian S. Posner joined our Board of Directors in 2008. Mr. Posner is a member of our Compensation Management and Development Committee. Mr. Posner has been a private investor since March 2008 and is the founder and Managing Partner of Point Rider Group, LLC, a boutique consulting and advisory services firm that provides customized solutions to senior executives and boards of financial, bio-pharmaceutical and other services-related companies, as well as strategic investors that make, direct and control investments in those sectors. From 2005 to March 2008 Mr. Posner served as the President, Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company and a wholly owned subsidiary of Legg Mason. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management, where he also served as co-Chief Investment Officer and Director of Research. Mr. Posner is also a member of the Board of Directors of Arch Capital Group Ltd., a specialty insurance and reinsurance provider, and a member of the Board of Trustees of AQR Mutual Funds, an investment fund.

Caroline D. Dorsa

Job Titles:
  • Chairman of Our Audit Committee
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Director and Chair, Audit Committee
Caroline D. Dorsa joined our Board of Directors in 2010. Ms. Dorsa serves as Chair of our Audit Committee. Ms. Dorsa served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group, Inc., a diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from February 2003 to April 2009. From February 2008 to April 2009 she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a pharmaceutical company. From November 2007 to January 2008 Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a life sciences company. From February 2007 to November 2007 she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a telecommunications company. From 1987 to January 2007 Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing and Executive Director of U.S. Pricing and Strategic Planning. Ms. Dorsa also serves on the Board of Directors of Intellia Therapeutics, Inc., a biotechnology company, and Illumina, Inc., a life sciences company, and as a Trustee of the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund, investment funds within the Goldman Sachs Asset Management fund complex.

Chirfi Guindo - EVP

Job Titles:
  • Executive Vice President
  • Executive Vice President and Head of Global Product Strategy
Chirfi Guindo is Executive Vice President and Head of Global Product Strategy and Commercialization. He has served on the Executive Committee since November 2017.

Eric K. Rowinsky

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Corporate Governance Committee
  • Member of Our Corporate Governance Committee
  • Member of the Boards of Directors of Fortress Biotech Inc
Eric K. Rowinsky, M.D., joined our Board of Directors in 2010. Dr. Rowinsky is a member of our Corporate Governance Committee. Dr. Rowinsky has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. Since June 2016 Dr. Rowinsky has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human proof-of-concept milestones. From January 2012 to November 2015 Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at the Cancer Therapy & Research Center's Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and was Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996 Dr. Rowinsky was an associate professor of oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is also a member of the Boards of Directors of Fortress Biotech Inc., Kitov Pharma Ltd. and Verastem, Inc., all of which are biopharmaceutical companies.

Ginger Gregory - CHRO, EVP

Job Titles:
  • Chief Human Resources Officer
  • Executive Vice President
  • Executive Vice President and Chief Human Resource Officer
Ginger Gregory, Ph.D., is Executive Vice President and Chief Human Resource Officer of Biogen and has served on the Executive Committee since July 2017. Dr. Gregory joined Biogen from Shire PLC, where she had served as Executive Vice President and Chief Human Resources Officer since 2014. Prior to joining Shire, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin' Brands, where she served as Chief Human Resource Officer; Novartis, AG, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health, and Novartis Institutes of BioMedical Research from 2005-2012; and Novo Nordisk, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, she held a variety of human resources generalist and specialist positions at Bristol Myers Squibb and served as a consultant with Booz Allen & Hamilton in the area of organization change and effectiveness. Dr. Gregory is a graduate of the University of Massachusetts and The George Washington University with a B.A., M.Phil. and Ph.D. in Psychology.

Honorable Lynn Schenk

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Member of Our Compensation and Management Development Committee
  • Member of the Board of Directors of Sempra Energy
Lynn Schenk joined our Board of Directors in 1995. Ms. Schenk is a member of our Compensation and Management Development Committee. Ms. Schenk is an attorney and consultant in private practice with extensive public policy and business experience. She is also a member of the Board of Overseers of the Scripps Research Institute, a director of the California High-Speed Rail Authority Board and a trustee of the University of California, San Diego Foundation. From 1999 to 2003 she served as Chief of Staff to the Governor of California, during which time she led the effort to create the Institutes for Science and Innovation at the University of California. From 1993 to 1995 Ms. Schenk was a Member of the United States House of Representatives, representing San Diego, California, and served on the House Energy & Commerce Committee with a special emphasis on biotechnology. From 1980 to 1983 she was the California Secretary of Business, Transportation and Housing, during which time she formed the California Commission on Industrial Innovation. During the California energy crisis and post-9/11/2001, Ms. Schenk headed the risk management team for the State of California's Executive Branch. Ms. Schenk is a member of the Board of Directors of Sempra Energy, an energy services and development company, and serves on the Corporate Governance Committee, the Executive Committee and is the Chair of the Environmental Health, Safety and Technology Committee. Ms. Schenk is also a National Association of Corporate Directors (NACD) Board Leadership Fellow, a member of the NACD Advisory Council on Risk Oversight and a Fellow of the UCLA Luskin School of Public Affairs. In 2017 Ms. Schenk was selected as an NACD Directorship 100 honoree.

Jeffrey D. Capello - CFO, EVP

Job Titles:
  • Certified Public Accountant
  • Chief Financial Officer
  • Executive Vice President
  • Member of the Executive Leadership Team
Jeffrey D. Capello is Executive Vice President and Chief Financial Officer of Biogen and has served on the Executive Committee since December 2017. Mr. Capello joined Biogen from Beacon Health Options, Inc., where he served as Executive Vice President and Chief Financial Officer. Mr. Capello was previously Chief Financial Officer of Ortho Clinical Diagnostics, Boston Scientific Corporation, and Perkin Elmer. His finance experience also includes the founding and running of his own company, Monomoy Advisors. Earlier in his career he was a partner in the Boston and Amsterdam offices of PwC. Mr. Capello is a certified public accountant. He holds a B.S. in Business Administration from the University of Vermont and an M.B.A. in Accounting from Harvard Business School.

Jesus B. Mantas

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Corporate Governance Committee
  • Member of Our Corporate Governance Committee
Jesus B. Mantas joined our Board of Directors in 2019. Mr. Mantas is a member of our Corporate Governance Committee. Mr. Mantas serves as the Senior Managing Partner for Global Strategy, Platforms and Innovation of IBM Global Business Services (GBS), a $17 billion unit of IBM. This includes strategy and transformation, global offerings, digital technology platforms, acquisitions, ventures and IBM Institute of Business Value, the thought leadership arm of IBM. From 2002 through 2016 Mr. Mantas led IBM's Business Consulting unit, IBM Global Process Services unit and the Business Services unit in Latin America after he held multiple leadership positions as Vice President in North America. Prior to IBM, Mr. Mantas was a Partner in PricewaterhouseCoopers Consulting, and an officer in the Air Force of Spain before that. Mr. Mantas has been a member of IBM Chairman's Acceleration Team for 10 years, and he chairs the IBM Hispanic diversity council. He has been recognized as one of the Top 25 Global Consulting leaders by Consulting magazine, and awarded multiple times for his contributions to Hispanic diversity in technology.

JOHANNA FRIEDL-NADERER

Job Titles:
  • DIRECTOR

JONATHAN MARK RANDELL

Job Titles:
  • DIRECTOR

LORRAINE DEBORAH BARR

Job Titles:
  • DIRECTOR

Michel Vounatsos - CEO

Job Titles:
  • Chief Executive Officer
  • Member of the Board of Directors
  • Member of the Executive Leadership Team
  • in 2016 As Executive Vice President, Chief Commercial Officer
Michel Vounatsos is Chief Executive Officer at Biogen and has served in this position and as a member of the Board of Directors since January 2017. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck's global primary care business unit, a role which encompassed Merck's cardiology-metabolic, general medicine, women's health and biosimilars groups and developed and instituted a strategic framework for enhancing the company's relationships with key constituents, including the most significant providers, payers and retailers and the world's largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Mr. Vounatsos currently serves as the Chairman of the Supervisory Board of the Electrophysiology and Heart Modeling Institute at the University of Bordeaux, on the Board of Directors of N-Unem Ultra-Rare Disease Foundation, on the advisory board of Tsinghua University School of Pharmaceutical Sciences and as a member of the MIT Presidential CEO Advisory Board.. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Nancy L. Leaming

Job Titles:
  • Member of Our Audit Committee
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Audit Committee
Nancy L. Leaming joined our Board of Directors in 2008. Ms. Leaming is a member of our Audit Committee. She has been an independent consultant since 2005. From 2003 to 2005 she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. From 1986 to 2003 Ms. Leaming served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer and Chief Financial Officer. Ms. Leaming currently sits on the Board of Directors of Rosie's Place, a not for profit, which was founded in 1974 as the first women's shelter in the United States. Today, Rosie's Place not only provides meals and shelter for 12,000 women, but also English and computer classes, legal assistance, wellness and mental health care and a food pantry. She chairs the Audit Committee.

NEIL RAYMOND SISAK

Job Titles:
  • Director
  • SENIOR DIRECTOR, HEAD OF FINANCE EUROPE

Richard C. Mulligan

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Compensation and Management Development Committee
  • Member of Our Compensation and Management Development Committee
Richard C. Mulligan, Ph.D., joined our Board of Directors in 2009. Dr. Mulligan is a member of our Compensation and Management Development Committee. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. Dr. Mulligan also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, a private biotechnology company. From March 2017 to October 2018 Dr. Mulligan served as a Portfolio Manager at Icahn Capital LP. Prior to that, he was Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. He was named a MacArthur Foundation Fellow in 1981.

Robert W. Pangia

Job Titles:
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Chairman of Our Compensation and Management Development Committee
  • Director and Chair, Compensation and Management Development Committee
Robert W. Pangia joined our Board of Directors in 1997. Mr. Pangia serves as Chair of our Compensation and Management Development Committee. Mr. Pangia has been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009 he also served as the Chief Executive Officer of Highlands Acquisition Corp., a special-purpose acquisition company. From 1996 to 2003 Mr. Pangia was self-employed as an investment banker. From 1987 to 1996 he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc. and a member of several of PaineWebber's executive and operating committees.

SIMON CHARLTON BECK

Job Titles:
  • DIRECTOR

Stelios Papadopoulos - Chairman

Job Titles:
  • Chairman of the Board
  • Member of the Audit Committee
  • Corporate Governance Committee
Stelios Papadopoulos, Ph.D., joined our Board of Directors in 2008 and was appointed as Chairman in June 2014. Dr. Papadopoulos is a member of our Corporate Governance Committee. Dr. Papadopoulos is the Chairman of the Board of Directors of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. He is also the Chairman of Regulus Therapeutics, Inc., a life sciences company. He co-founded Anadys Pharmaceuticals, Inc., a biopharmaceutical company, in 2000 and was a member of its Board of Directors until its acquisition by Hoffman-La Roche in 2011, serving as the Chairman of the board during 2011. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke Medicine and a member of the Global Advisory Board of the Duke Institute for Health Innovation. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC, a financial services company, in 2006, after six years with the firm where, as an investment banker, he focused on the biotechnology and pharmaceutical sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Inc., where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where, as an analyst in the Equity Research Department, he covered the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University School of Medicine. He maintains his affiliation with NYU as an adjunct associate professor of cell biology.

Stephen A. Sherwin

Job Titles:
  • Member of Our Audit Committee
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Audit Committee
  • Member of the Boards of Directors of Aduro Biotech, Inc
Stephen A. Sherwin, M.D., joined our Board of Directors in 2010. Dr. Sherwin is a member of our Audit Committee. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo BioSciences, Inc. in 2013. He was also co-founder and Chairman of Abgenix, Inc., an antibody company that was acquired by Amgen Inc. in 2006. From 1990 to October 2009 he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company's merger with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is board certified in internal medicine and medical oncology. Dr. Sherwin is also a member of the Boards of Directors of Aduro Biotech, Inc., Neurocrine Biosciences, Inc. and Neon Therapeutics, Inc., which are all life sciences companies.

STEVEN JOHN GREEN - CFO

Job Titles:
  • Director
  • FINANCE DIRECTOR

Susan H. Alexander - Chief Legal Officer, EVP

Job Titles:
  • Chief Legal Officer
  • Executive Vice President
  • Member of the Executive Leadership Team
  • Secretary
Susan H. Alexander is Executive Vice President, Chief Legal Officer and Secretary of Biogen, and has served on the Executive Committee since 2006. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. Ms. Alexander received her B.A. from Wellesley College and her J.D. from Boston University School of Law.

TERRY MILTON O'REGAN

Job Titles:
  • DIRECTOR

TREVOR ANTHONY MILL

Job Titles:
  • Director
  • PHARMACIST

William A. Hawkins

Job Titles:
  • Member of Our Audit Committee
  • Member of the Audit Committee
  • Member of the Board of Directors
  • Audit Committee
  • Member of the Board of Directors for Avanos Medical, Inc
William A. Hawkins joined our Board of Directors in 2019. Mr. Hawkins is a member of our Audit Committee. Mr. Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation, an interventional cardiology company. Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves as Chairman of Bioventus, LLC and of 4 Tech and as a director of Trice Medical, Inc., AsKBio, Virtue labs, Cerius, Keratin Biosciences and Baebies, Inc., all of which are medical products companies. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. He has a dual degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia' s Darden School of Business. Mr. Hawkins is also a member of the Board of Directors for Avanos Medical, Inc., a medical technology company.